

# Haidong D Dong

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5163454/haidong-d-dong-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129 papers	19,106 citations	53 h-index	138 g-index
144 ext. papers	22,017 ext. citations	9.1 avg, IF	6.12 L-index

#	Paper	IF	Citations
129	PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF- $\beta$ receptor I versus II.. <i>Cell Reports</i> , <b>2022</b> , 38, 110349	10.6	0
128	Understanding Suboptimal Response to Immune Checkpoint Inhibitors.. <i>Advanced Biology</i> , <b>2022</b> , e2101319		1
127	Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade.. <i>Advances in Radiation Oncology</i> , <b>2022</b> , 7, 100931	3.3	0
126	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.. <i>BMJ Open</i> , <b>2022</b> , 12, e050112	3	1
125	Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 22	9.8	2
124	Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 378-386	7.5	3
123	PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	11
122	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 86	7	4
121	ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 952-966	12.5	3
120	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 135.e1-135.e8	2.8	1
119	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	4
118	Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , <b>2021</b> , 5, 129-135	0.6	
117	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6376-6383	12.9	4
116	Immune signatures underlying post-acute COVID-19 lung sequelae. <i>Science Immunology</i> , <b>2021</b> , 6, eabk1748	17.4	16
115	Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
114	Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. <i>Nuclear Medicine and Biology</i> , <b>2021</b> , 100-101, 4-11	2.1	0
113	NKG7 is a T-cell intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy.. <i>Cancer Immunology Research</i> , <b>2021</b> ,	12.5	2

112	Radiation and immunotherapy: emerging mechanisms of synergy. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 7011-7023	2.6	11
111	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>OncoImmunology</i> , <b>2020</b> , 9, 1744980	7.2	40
110	Regulation of sister chromatid cohesion by nuclear PD-L1. <i>Cell Research</i> , <b>2020</b> , 30, 590-601	24.7	26
109	Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. <i>Nature Immunology</i> , <b>2020</b> , 21, 365-366	19.1	5
108	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 967-978	1	27
107	Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. <i>JAMA Network Open</i> , <b>2020</b> , 3, e200202	10.4	12
106	Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5380-5396	15.9	48
105	Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1152-1160	4.8	9
104	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , <b>2020</b> , 30, 364-375	3.3	16
103	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles <b>2020</b> , 8,		12
102	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 561083	8.4	7
101	The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8 T Cell Fitness and Functionality. <i>Immunity</i> , <b>2019</b> , 51, 491-507.e7	32.3	70
100	Paradox-driven adventures in the development of cancer immunology and immunotherapy. <i>Genes and Diseases</i> , <b>2019</b> , 6, 224-231	6.6	3
99	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. <i>Molecular Cell</i> , <b>2019</b> , 74, 1215-1226.e4	17.6	73
98	BRAF-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. <i>Oncogene</i> , <b>2019</b> , 38, 6752-6766	9.2	30
97	Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. <i>Future Oncology</i> , <b>2019</b> , 15, 2645-2656	3.6	6
96	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. <i>Scientific Reports</i> , <b>2019</b> , 9, 10677	4.9	26
95	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 22	7	28

94	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , <b>2019</b> , 24, e1148-e1155	5.7	45
93	Prospective Immunophenotyping of CD8 T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 103, 229-240	4	11
92	Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 276-287	8.9	61
91	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF- $\kappa$ B Activation and PD-L1 Expression. <i>Molecular Cell</i> , <b>2019</b> , 73, 22-35.e6	17.6	108
90	First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. <i>Oncologist</i> , <b>2018</b> , 23, 840-843	5.7	8
89	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3299-3308	12.9	27
88	Contraction of T cell richness in lung cancer brain metastases. <i>Scientific Reports</i> , <b>2018</b> , 8, 2171	4.9	50
87	The Basic Concepts in Cancer Immunology and Immunotherapy <b>2018</b> , 1-19		0
86	Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , <b>2018</b> , 78, 97-105	3.7	6
85	Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. <i>European Urology Focus</i> , <b>2018</b> , 4, 75-79	5.1	15
84	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1739	8.4	112
83	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , <b>2018</b> , 560, 382-386	50.4	1058
82	CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	62
81	Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. <i>American Journal of Reproductive Immunology</i> , <b>2018</b> , 79, e12795	3.8	52
80	Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. <i>Heliyon</i> , <b>2018</b> , 4, e01039	3.6	23
79	Targeting IFN $\gamma$ to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. <i>Nature Communications</i> , <b>2018</b> , 9, 4586	17.4	30
78	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 580-588	15.9	259
77	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , <b>2017</b> , 129, 3419-3427	2.2	244

76	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. <i>Gastroenterology</i> , <b>2017</b> , 153, 1107-1119.e10	13.3	201
75	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. <i>American Journal of Clinical Pathology</i> , <b>2017</b> , 148, 441-449	1.9	11
74	Type II phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF- $\kappa$ B. <i>Oncotarget</i> , <b>2017</b> , 8, 42414-42427	3.3	17
73	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. <i>Onc Immunology</i> , <b>2017</b> , 6, e1356146	7.2	23
72	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 961	8.4	70
71	B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1532	8.4	14
70	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 1960-1977	15.9	58
69	Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11534-11534	2.2	12
68	A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. <i>SOJ Immunology</i> , <b>2017</b> , 5, 1-5		
67	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8 T cells. <i>Scientific Reports</i> , <b>2016</b> , 6, 36722	4.9	26
66	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- $\kappa$ B. <i>Cancer Research</i> , <b>2016</b> , 76, 239-50	10.1	62
65	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , <b>2016</b> , 128, 4392-4392	2.2	7
64	CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. <i>Oncotarget</i> , <b>2016</b> , 7, 70223-70231	3.3	27
63	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	52
62	Immunomodulatory antibody therapy of cancer: the closer, the better. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 944-6	12.9	10
61	Immunotherapy in prostate cancer. <i>Current Urology Reports</i> , <b>2015</b> , 16, 34	2.9	6
60	Stem cells for murine interstitial cells of cajal suppress cellular immunity and colitis via prostaglandin E2 secretion. <i>Gastroenterology</i> , <b>2015</b> , 148, 978-90	13.3	23
59	A gender factor in shaping T-cell immunity to melanoma. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 8	5.3	11

58	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 610-9	12.5	251
57	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , <b>2015</b> , 126, 834-834	2.2	15
56	B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 859-67	7.4	11
55	B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1036-1040	8.9	177
54	A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3049-3049	2.2	
53	Endogenous tumor-reactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. <i>OncolImmunology</i> , <b>2013</b> , 2, e23972	7.2	30
52	A novel method to identify and monitor endogenous tumor-reactive T cells by high expression of CD11a (LFA-1) and PD-1 (CD279) as immunologic readout for evaluating the efficacy of PD-1 blockade.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3037-3037	2.2	
51	Soluble B7-H1: differences in production between dendritic cells and T cells. <i>Immunology Letters</i> , <b>2012</b> , 142, 78-82	4.1	86
50	B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. <i>OncolImmunology</i> , <b>2012</b> , 1, 1061-1073	7.2	33
49	Immunotherapeutic approaches to hepatocellular carcinoma treatment. <i>Liver Cancer</i> , <b>2012</b> , 1, 226-37	9.1	43
48	B7-h1 expressed by activated CD8 T cells is essential for their survival. <i>Journal of Immunology</i> , <b>2011</b> , 187, 5606-14	5.3	48
47	Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1915-23	12.9	235
46	Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. <i>Journal of Immunology</i> , <b>2011</b> , 186, 6905-13	5.3	179
45	Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 160-9	7	56
44	B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. <i>Journal of Immunology</i> , <b>2010</b> , 184, 5466-5474	5.3	27
43	B7-H1 expression in vestibular schwannomas. <i>Otology and Neurotology</i> , <b>2010</b> , 31, 991-7	2.6	24
42	TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. <i>Journal of Immunology</i> , <b>2009</b> , 183, 3634-41	5.3	92
41	MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. <i>Journal of Immunology</i> , <b>2009</b> , 182, 1325-33	5.3	163

40	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. <i>Blood</i> , <b>2009</b> , 114, 2149-58	2.2	162
39	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma <b>2009</b> , 367-403		
38	New Strategies to Improve Tumor Cell Vaccine Therapy <b>2009</b> , 117-131		
37	Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5150-7	12.9	200
36	The reverse signals of costimulatory molecule B7-H1 negatively regulate memory CD8 T cell function in tumor immunity. <i>FASEB Journal</i> , <b>2008</b> , 22, 523-523	0.9	
35	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. <i>Cancer</i> , <b>2007</b> , 109, 1499-505	6.4	322
34	Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. <i>Journal of Immunology</i> , <b>2007</b> , 179, 2860-9	5.3	61
33	Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2075-81	12.9	168
32	Costimulation, coinhibition and cancer. <i>Current Cancer Drug Targets</i> , <b>2007</b> , 7, 15-30	2.8	79
31	PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1757-61	12.9	431
30	Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1749-56	12.9	88
29	Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 709s-715s	12.9	168
28	Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. <i>Cancer</i> , <b>2006</b> , 107, 46-53	6.4	61
27	Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. <i>Cancer Research</i> , <b>2006</b> , 66, 3381-5	10.1	696
26	B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 10391-10396	11.5	252
25	Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function. <i>Journal of Immunology</i> , <b>2006</b> , 177, 6730-7	5.3	39
24	Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. <i>Cellular and Molecular Immunology</i> , <b>2006</b> , 3, 179-87	15.4	58
23	B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. <i>Urology</i> , <b>2005</b> , 66, 10-4	1.6	42



22	Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. <i>Cancer</i> , <b>2005</b> , 104, 2084-91	6.4	149
21	Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5708-17	12.9	89
20	Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. <i>Cancer Research</i> , <b>2005</b> , 65, 1089-96	10.1	649
19	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 17174-9	11.5	657
18	B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. <i>Journal of Immunology</i> , <b>2004</b> , 173, 5445-50	5.3	144
17	Augmentation of T cell levels and responses induced by androgen deprivation. <i>Journal of Immunology</i> , <b>2004</b> , 173, 6098-108	5.3	188
16	B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. <i>Immunity</i> , <b>2004</b> , 20, 327-36	32.3	317
15	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. <i>Blood</i> , <b>2003</b> , 101, 2514-20	2.2	149
14	Immunology of B7-H1 and its roles in human diseases. <i>International Journal of Hematology</i> , <b>2003</b> , 78, 321-8	2.3	33
13	B7-H1 pathway and its role in the evasion of tumor immunity. <i>Journal of Molecular Medicine</i> , <b>2003</b> , 81, 281-7	5.5	223
12	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , <b>2003</b> , 9, 562-7	50.5	980
11	Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 197, 1083-91	16.6	233
10	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 363-70	15.9	147
9	B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. <i>Cancer Research</i> , <b>2003</b> , 63, 6501-5	10.1	359
8	Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. <i>Nature Medicine</i> , <b>2002</b> , 8, 793-800	50.5	3475
7	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. <i>Blood</i> , <b>2001</b> , 97, 1809-16	2.2	179
6	B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. <i>Nature Immunology</i> , <b>2001</b> , 2, 269-74	19.1	705
5	Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. <i>Blood</i> , <b>2000</b> , 96, 2808-2813	2.2	207



4	Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. <i>Blood</i> , <b>2000</b> , 96, 2808-2813	2.2	13
3	B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. <i>Nature Medicine</i> , <b>1999</b> , 5, 1365-9	50.5	1874
2	B7-H1(PD-L1) confers chemoresistance through ERK and p38 MAPK pathway in tumor cells		2
1	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion		1